Trial Profile
Voiding Efficiency, a Predictor of CIC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Allergan
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2019 Planned End Date changed from 29 Aug 2019 to 30 Sep 2019.
- 29 Jul 2019 Planned End Date changed from 30 Jun 2019 to 29 Aug 2019.